

POSTER LIST



1. Peer education as a strategy to promote vaccine acceptance: a randomized controlled trial within New York community healthcare practices

[Dr. Ellie Carmody](#)

2. Acceptability and Trust in the Low-dose Intradermal Mpox Vaccine: A Knowledge, Attitudes and Practices Survey Analysis within the Observational Study of Mpox Immunity (OSMI) in NYC

[Dr. Ellie Carmody](#)

3. A Summary of the University of Washington Participant Registry Data

[Dr. Tia Babu and Dr. Jessica Heimonen](#)

4. High throughput ELISA methodology for evaluating Sm-p80 humoral immunity in the Phase I Clinical Trial of the SchistoShield® vaccine.

[Dr. Rhea Coler](#)

5. Natural killer cell immunoregulation requires CD4 T cell expression of the transcription factor KLF2.

[Dr. Andrew Cox](#)

6. Antibody and T cell responses to an inactivated whole virus Zika vaccine (ZPIV) in flavi-naïve and flavi-experienced people

[Dr. Sarah George](#)

7. Effect of Omicron-containing vs. prototype insert one-dose mRNA vaccination on COVID-19 infections in the COVAIL study

[Dr. Daniel Graciaa](#)

8. Evaluating the impact of study design for vaccine effects on SARS-CoV-2 transmission: a mathematical modeling analysis.

[Dr. Laura Matrajt](#)



POSTER LIST



9. Differential antiviral SARS-CoV-2 memory CD4 T cell responses in pre- and post-pandemic children and adults
[Dr. Jennifer Nayak](#)
10. Treatment Emergent and Community Acquired RSV Mutations in Premature Infants: A Study Plan
[Dr. Erin Nicholson](#)
11. Safety and immunogenicity of fractional doses of Modified Vaccinia Ankara-Bavarian Nordic
[Dr. Zacharoula Oikonomopoulou](#)
12. A Phase I Trial to Examine the Safety and Immunogenicity of MVA-BN[®]-Filo and Ad26.ZEBOV Vaccines in Healthy Adults and Gene Expression Biomarkers Predicting Antibody Responses
[Dr. Christina Rostad](#)
13. MVA-BN induces a low avidity, non-durable humoral response against mpox virus
[Dr. Marie Samanovic-Golden](#)
14. An Assessment of Immunogenicity of licensed RSV vaccines in residents of Long-Term Care Facilities (LTCF) and community-dwelling older adults planning Respiratory Syncytial Virus (RSV) vaccination.
[Dr. Edward Walsh](#)

